SCHEMBL13259261

SCHEMBL13259261

COP(=O)(CCC(C)(CCCc1ccc(Sc2cccc(OCc3ccccc3)c2)cc1Cl)NC(=O)OC(C)(C)C)OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 4/20 0.51
S1PR3 Q99500 1/20 0.34
FFAR1 O14842 2/20 0.33
CYP2C9 P11712 1/20 0.33
PTGER1 P34995 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
SMPD1 P17405 1/20 0.33
BCL2 P10415 2/20 0.32
MCL1 Q07820 1/20 0.32
MTNR1B P49286 1/20 0.32
ALDH1A1 P00352 1/20 0.32
PDK1 Q15118 1/20 0.32
PDK2 Q15119 1/20 0.32
PDK3 Q15120 1/20 0.32
PDK4 Q16654 1/20 0.32
PRKX P51817 1/20 0.32
ACVR1 Q04771 1/20 0.32
S1PR5 Q9H228 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1563185 0.93 S1PR1 (0.54) S1PR1S1PR3FFAR1CYP2C9PTGER1
SCHEMBL13259308 0.90 S1PR1 (0.48) S1PR1S1PR3FFAR1CYP2C9PTGER1
SCHEMBL1563551 0.89 S1PR1 (0.54) S1PR1S1PR3FFAR1CYP2C9PTGER1
SCHEMBL13259318 0.89 S1PR1 (0.52) S1PR1S1PR3FFAR1CYP2C9PTGER1
SCHEMBL13259280 0.88 S1PR1 (0.48) S1PR1S1PR3FFAR1CYP2C9PTGER1
SCHEMBL13259260 0.85 S1PR1 (0.51) S1PR1S1PR3FFAR1CYP2C9PTGER1
SCHEMBL1563324 0.85 S1PR1 (0.57) S1PR1S1PR3FFAR1HDAC1HDAC8
SCHEMBL13259292 0.85 S1PR1 (0.51) S1PR1S1PR3CYP2C9PTGER1HDAC1
SCHEMBL1563388 0.85 S1PR1 (0.57) S1PR1S1PR3FFAR1CYP2C9PTGER1
SCHEMBL1563356 0.85 S1PR1 (0.59) S1PR1S1PR3CYP2C9PTGER1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759326-B2 Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-7456157-B2 Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-11-25 US disclosed
US-20080275008-A1 Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus KOHNO YASUSHI 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275008-A1 Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus S1PR1, S1PR2, S1PR5 S1PR1 1/4885S1PR3 4/4885FFAR1 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.